PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 189 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2014. The put-call ratio across all filers is 1.53 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $466,554 | +204.5% | 88,029 | +148.8% | 0.00% | +200.0% |
Q4 2023 | $153,230 | +57.8% | 35,388 | -4.1% | 0.00% | 0.0% |
Q3 2023 | $97,092 | +26.8% | 36,917 | +70.2% | 0.00% | 0.0% |
Q2 2023 | $76,573 | -82.1% | 21,692 | -84.3% | 0.00% | -66.7% |
Q1 2023 | $426,970 | +33.8% | 138,178 | +83.2% | 0.00% | +50.0% |
Q4 2022 | $319,103 | +459.8% | 75,438 | +212.6% | 0.00% | – |
Q3 2022 | $57,000 | -71.4% | 24,136 | -65.5% | 0.00% | -100.0% |
Q2 2022 | $199,000 | +77.7% | 69,938 | +80.2% | 0.00% | 0.0% |
Q1 2022 | $112,000 | -17.6% | 38,806 | -13.5% | 0.00% | 0.0% |
Q4 2021 | $136,000 | -39.0% | 44,867 | +41.0% | 0.00% | -66.7% |
Q3 2021 | $223,000 | -53.9% | 31,824 | -39.6% | 0.00% | -40.0% |
Q2 2021 | $484,000 | +148.2% | 52,694 | +162.4% | 0.01% | +150.0% |
Q1 2021 | $195,000 | -7.1% | 20,082 | -0.2% | 0.00% | -50.0% |
Q2 2020 | $210,000 | -70.5% | 20,125 | -76.1% | 0.00% | -78.9% |
Q1 2020 | $711,000 | +5.5% | 84,209 | +9.3% | 0.02% | +58.3% |
Q4 2019 | $674,000 | +17.4% | 77,010 | +44.5% | 0.01% | +9.1% |
Q3 2019 | $574,000 | -55.1% | 53,277 | -47.1% | 0.01% | -52.2% |
Q2 2019 | $1,279,000 | +28.3% | 100,663 | +291.7% | 0.02% | -28.1% |
Q1 2019 | $997,000 | +823.1% | 25,697 | +384.8% | 0.03% | +540.0% |
Q4 2018 | $108,000 | -70.7% | 5,300 | -34.0% | 0.01% | -75.0% |
Q3 2018 | $368,000 | +1433.3% | 8,035 | +1908.8% | 0.02% | +1900.0% |
Q2 2018 | $24,000 | -68.0% | 400 | -63.7% | 0.00% | -75.0% |
Q1 2018 | $75,000 | -63.4% | 1,102 | -47.0% | 0.00% | -63.6% |
Q4 2017 | $205,000 | +72.3% | 2,078 | +109.9% | 0.01% | +57.1% |
Q3 2017 | $119,000 | -18.5% | 990 | -40.6% | 0.01% | -22.2% |
Q2 2017 | $146,000 | -13.6% | 1,668 | -69.8% | 0.01% | -30.8% |
Q4 2016 | $169,000 | +160.0% | 5,521 | +472.1% | 0.01% | +225.0% |
Q3 2016 | $65,000 | -39.8% | 965 | -73.3% | 0.00% | -33.3% |
Q2 2016 | $108,000 | -91.2% | 3,610 | -91.4% | 0.01% | -91.4% |
Q1 2016 | $1,228,000 | +113.6% | 41,809 | +469.6% | 0.07% | +105.9% |
Q4 2015 | $575,000 | +492.8% | 7,340 | +467.7% | 0.03% | +580.0% |
Q3 2015 | $97,000 | -92.2% | 1,293 | -87.8% | 0.01% | -91.8% |
Q2 2015 | $1,238,000 | +435.9% | 10,603 | +984.2% | 0.06% | +454.5% |
Q1 2015 | $231,000 | +1.8% | 978 | -18.5% | 0.01% | -8.3% |
Q4 2014 | $227,000 | – | 1,200 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Cormorant Asset Management, LP | 507,500 | $121,074,000 | 24.90% |
BB BIOTECH AG | 476,991 | $113,796,000 | 4.63% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $1,356,668,000 | 3.35% |
WEATHERBIE CAPITAL, LLC | 101,055 | $24,109,000 | 2.26% |
Avalon Global Asset Management LLC | 16,000 | $3,817,000 | 2.24% |
Redmile Group, LLC | 51,025 | $12,173,000 | 1.41% |
Fernwood Investment Management, LLC | 6,700 | $1,598,000 | 1.38% |
Iguana Healthcare Management, LLC | 10,000 | $2,386,000 | 1.27% |
LMR Partners LLP | 56,632 | $13,510,000 | 1.08% |
FRANKLIN STREET ADVISORS INC /NC | 21,990 | $5,246,000 | 1.00% |